Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women

(2010) Mickaël Hiligsmann et al.   BONE

Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications

(2010) Mickaël Hiligsmann et al.   CALCIFIED TISSUE INTERNATIONAL

The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients

(2010) Mickaël Hiligsmann et al.   HEALTH POLICY

A FRAX® model for the assessment of fracture probability in Belgium

(2010) H. Johansson et al.   OSTEOPOROSIS INTERNATIONAL

Cost–Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence

(2010) Mickaël Hiligsmann et al.   VALUE IN HEALTH

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

(2009) Ethel S. Siris et al.   AMERICAN JOURNAL OF MEDICINE

FRAX® and its applications to clinical practice

(2009) John A. Kanis et al.   BONE

Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years

(2009) Mickaël Hiligsmann et al.   BONE

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence

(2009) Véronique Rabenda et al.   EXPERT OPINION ON PHARMACOTHERAPY

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

(2009) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women

(2009) M. Hiligsmann et al.   OSTEOPOROSIS INTERNATIONAL

Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting

(2009) O. Ström et al.   OSTEOPOROSIS INTERNATIONAL

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

(2009) I. Imaz et al.   OSTEOPOROSIS INTERNATIONAL

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

(2009) Johann D. Ringe et al.   RHEUMATOLOGY INTERNATIONAL

Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis

(2009) Mickaël Hiligsmann et al.   VALUE IN HEALTH

Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women

(2008) Mickaël Hiligsmann et al.   BONE

Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature

(2008) Mickaël Hiligsmann et al.   CALCIFIED TISSUE INTERNATIONAL

Differences in persistence among different weekly oral bisphosphonate medications

(2008) O. Sheehy et al.   OSTEOPOROSIS INTERNATIONAL

Incorporating adherence into health economic modelling of osteoporosis

(2008) O. Ström et al.   OSTEOPOROSIS INTERNATIONAL

Cost-effective osteoporosis treatment thresholds: the United States perspective

(2008) A. N. A. Tosteson et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Belgian Methodological Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Requests

(2008) Irina Cleemput et al.   VALUE IN HEALTH

An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis

(2008) Mickaël Hiligsmann et al.   Disease management & health outcomes.

Is denosumab better than alendronate in the treatment of osteoporosis?

(2008) E Michael Lewiecki   Nature clinical practice. Rheumatology

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH

Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis

(2006) Carolyn M. Klotzbuecher et al.   JOURNAL OF BONE AND MINERAL RESEARCH